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ABSTRACT  
 
Objective: To assess the connection between amyloid pathology and white matter 
(WM) macro- and micro-structural damage in demented patients compared with 
controls. 
Methods: Eighty-five participants were recruited: 65 with newly diagnosed Alzheimer’s 
disease (AD), non-AD dementia or mild cognitive impairment (MCI), and 20 age- and 
sex-matched heatlhy controls. β-amyloid1-42  (Aβ) levels were determined in 
cerebrospinal fluid (CSF) samples from all patients and 5 controls.  Among patients, 42 
had pathological CSF Aβ levels (Aβ+), while 23 had normal CSF Aβ levels (Aβ-). All 
participants underwent neurological examination, neuropsychological testing and brain 
magnetic resonance imaging (MRI). We used T2-weighted scans to quantify white 
matter (WM) lesion loads (LL), and diffusion weighted images (DWI) to assess their 
microstructural substrate. Non-parametric statistical tests were used for between-group 
comparisons and multiple regression analyses. 
Results: We found an increased WM-LL in Aβ(+) compared to both, healthy controls 
(p=0.003) and Aβ(-) patients (p=0.02). Interestingly, CSF Aβ concentration was the best 
predictor patients’ WM-LL (r=-0.30, p<0.05) when using age as a covariate. Lesion 
apparent diffusion coefficient (ADC) value was higher in all patients than in controls 
(p=0.0001), and correlated with WM-LL (r=0.41, p=0.001). In Aβ(+), WM-LL correlated 
with WM microstructural damage in the left peritrigonal WM (p<0.0001). 
Conclusions: WM damage is crucial in Alzheimer’s disease (AD) pathogenesis. The 
correlation between CSF Aβ levels and WM-LL suggests a direct link between amyloid 
pathology and WM macro- and microstructural damage. 
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INTRODUCTION 
In patients with Alzheimer's disease (AD), magnetic resonance imaging (MRI) 
often shows focal hyperintensities in the deep and subcortical white matter (WM).1-5 
Their nature remains unclear: the main hypothesis considers them as chronic ischemic 
lesions caused by cerebral microangiopathy,6,7 while neuropathological studies show 
evidence of demyelination and axonal loss.5,8 Thus, other mechanisms could be 
implicated, including blood-brain barrier leakage, inflammation, neurodegeneration, and 
amyloid angiopathy.5  A direct link between WM hyperintensities (WMHs) and the 
severity of cognitive decline has already been demonstrated in literature.9,10 The 
incidence of WMHs is higher in patients with AD,11-13 vascular dementia (VaD),14 
dementia with Lewy body (DLB),14 and frontotemporal dementia (FTD)15 (including 
some inherited forms of FTD,16-18). Moreover, the presence of WMHs seems to increase 
the risk for conversion from mild cognitive impairment (MCI) to AD, and to predict the 
progression of cognitive symptoms.10,11,19,20 Diffusion weighted imaging (DWI) studies 
have demonstrated the presence of WM microstructural changes in AD brains at 
preclinical stages.3 In our study, we chose to use apparent diffusion coefficient (ADC) 
maps, obtained from DWI scans, as metrics to state the integrity of WM at microscopic 
level. The Dominantly Inherited Alzheimer Network analyzed the severity and 
distribution of WMHs in pre-symptomatic presenilin 1, presenilin 2, and amyloid 
precursor protein mutation carriers, investigating the extent to which WMHs manifest  
genetically predisposed individuals.21 This study found that WMHs are elevated well 
before symptom onset, suggesting that WMHs are a core feature of AD pathogenesis.21 
Against this background, the contribution of WMHs to AD pathogenesis is still 
debated, and WMHs are mostly considered as a comorbidity rather than part of AD 
pathophysiology.4,10,21   
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To the best of our knowledge, only few data are available in literature on the 
relationship between measures of macro- and micro-structural WM damage and 
cerebrospinal fluid (CSF) biomarkers of neurodegeneration. Kalheim and colleagues 
reported a remarkable extent of WM microstructrual damage in patients with MCI who 
showed pathological CSF levels of β-amyloid1-42 (Aβ).22 Addictionally, an elegant paper 
by Dean III et al. has contributed in clarifying the relationship between amyloid 
pathology and myelin alteration in preclinical AD.23 Measuring whole-brain longitudinal 
and transverse relaxation times and the myelin water fraction (MWF), a significantly 
negative relationship between MWF and CSF Aβ levels was observed. Concerning 
inherited forms of AD, Lee and colleagues reported a correlation between WMHs and 
CSF Aβ levels.21 Finally, Noh and colleagues, using 11C-Pittsburgh compound B (PiB) 
PET imaging, demonstrated an association between WMH extension and amyloid 
burden.24 
To better understand the relationship between WMHs and amyloid pathology, we 
aimed here at investigating how CSF Aβ and tau levels interact with measures of 
macro- and micro-structural WM damage and grey matter (GM) atrophy in patients with 
AD.  
 
MATERIALS AND METHODS 
Subjects 
Sixty-five patients with cognitive deficits were consecutively recruited at the 
Alzheimer Center of the University of Milan, Policlinico Hospital (Milan, Italy). All 
patients underwent a clinical interview, neurological and neuropsychological 
examination, routine blood tests, brain MRI, and lumbar puncture (LP) for quantification 
of the CSF biomarkers Aβ, total tau (tau), and tau phosphorylated at position 181 
(Ptau). Cut-off thresholds of normality were: Aβ ≥600 pg/ml; tau ≤500 pg/ml for 
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individuals older than 70 and ≤450 pg/ml for individuals aged between 50 and 70 years; 
Ptau ≤61 pg/ml.25 For the purpose of this study, patients with CSF Aβ levels <600 pg/ml 
were classified as Aβ(+), while patients with CSF Aβ levels within the normal range 
were classified as Aβ(-). Similar classification was applied to tau and Ptau CSF levels. 
Fourty-two patients were diagnosed with AD, as confirmed by their pathological 
CSF Aβ levels, according to the criteria of the International Working Group guidelines.26 
Twenty-three patients (all with normal CSF Aβ levels) were diagnosed with a non-AD 
form of neurodegenerative dementia.  
To minimize the risk of confounding variables associated with vascular 
comorbidities (i.e. subcortical vascular dementia), we selected only patients with a 
Hachinski Ischaemic score (HIS) <327, a periventricular and deep white matter Fazekas 
score ≤21, without any relevant history or risk factor for cardiovascular disease. In 
particular, patients suffering from diabetes, atrial fibrillation, arterial hypertension or with 
a history of stroke or myocardial infarction were excluded from the study. 
Twenty age- and sex-matched controls who volunteered to undergo 
neuropsychological assessment and brain MRI were also enrolled. Among them, 5 
individuals agreed to undergo LP. All these subjects were clinically followed-up for 
almost three years and none of them developed any symptom or sign suggestive for 
cognitive decline. 
The main demographic and clinical characteristics of all recruited subjects are 
summarized in Table 1. 
 The current study was approved by the Institutional Review Board of the 
Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico (Milan, Italy). All patients 
(or their legal guardians) and controls gave their written informed consent for this 
research before entering the study.  
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CSF collection and Aβ and tau determination 
CSF samples were collected by LP in the L3/L4 or L4/L5 interspace. The LP was 
done between 8 and 10 a.m. after one-night fasting. Then, CSF samples were 
centrifuged in 8000 rpm for 10 minutes. The supernatants were aliquoted in 
polypropylene tubes and stored at – 80 °C until use. CSF cell counts, glucose, and 
proteins were determined. CSF Aβ, tau and Ptau were measured using, respectively, 
three commercially available sandwich enzyme-linked immunosorbent assay (ELISA) 
kits (Fujirebio, Ghent, Belgium).  
 
MRI acquisition 
All patients underwent a MRI examination on Achieva 3T scanner (Philips, The 
Netherlands). The acquisition protocol included: 1) a 3D T1-weighted scan (TR 9.90 ms; 
TE 4.61 ms; Flip angle 8°; slices thickness 1 mm; gap 0) 2) a T2-weighted scan (TR 
2492 ms; TE 78 ms; Flip angle 90°; slices thickness 4 mm; gap 0); 3) a Fluid attenuated 
inversion recovery (FLAIR) scan (TR 11000 ms; TE 125 ms; Flip angle 90°; slices 
thickness 2 mm; gap 0); 4) a Diffusion weighted imaging (DWI) scan (b-value 1000 
s^2/mm ; TR 2733 ms; TE 53 ms; Flip angle 90°; slices thickness 4 mm; gap 0). 
 
WM macrostructual damage 
To quantify the macroscopic load, WMHs were first identified on FLAIR scans by 
consensus of three independent observers (MS; PB; TC). WMHs were then outlined 
using a semi-automated local threshold contouring technique (Jim 7.0, Xinapse System, 
Leicester, UK, http://www.xinapse.com/). For each dataset, the WM lesion load (WM-
LL) was calculated and used for correlation analyses. Additionally, as explained below, 
WM lesion masks were overlapped to diffusion imaging data to obtain a measure of 
microscopic tissue damage. 
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Brain volumetrics 
All 3D T1-weighted scans were first visually inspected to exclude the presence of 
macroscopic artefacts. Data were processed using an optimized voxel-based 
morphometry (VBM) protocol in Statistical Parametric Mapping 8 (SPM8; Wellcome 
Department of Imaging Neuroscience; www.fil.ion.ucl.ac.uk/spm/). Segmentation and 
normalization produced a GM probability map28 in Montreal Neurological Institute 
coordinates. To compensate for compression or expansion during warping of images to 
match the template, GM maps were modulated by multiplying the intensity of each voxel 
by the local value derived from the deformation field.29 All data were then smoothed 
using a 8-mm full width half maximum (FWHM) Gaussian kernel. Then, GM maps were 
analysed in SPM8, using a sample t-test for the comparison between groups and a 
regression model to assess possible associations between patients’ regional GM 
volumes and other variables of interest. We derived for each scan the GM fraction, 
calculated as the ratio of total GM volume to total intracranial volume (TIV). Age, 
gender, disease duration and Mini Mental State Examination (MMSE) scores were 
always entered as covariates of no interest. For every T-contrast, we applied the family 
wise error (FWE) correction for multiple comparisons, and we accepted as significant p 
values < 0.05 (corrected at cluster level). 
 
WM microstructural damage  
 FLAIR images were coregistered to ADC maps using ANTs30 after having 
skullstripped both images. The same transformation was applied to the lesion mask in 
order to project them into the ADC space. Finally, for each subject, we derived the 
mean value of ADC inside the lesions. This analysis aimed at investigating whether 
specific neurobiological substrates existed across groups, and whether there was any 
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association between them and the CSF biomarkers. To this purpose, ADC maps were 
analysed in SPM8, using a regression model to assess possible associations between 
WM microstructural damage and other variables of interest (WM-LL, GM fraction and 
CSF biomarkers). For every T-contrast, we applied the family wise error (FWE) 
correction for multiple comparisons, and we accepted as significant p values < 0.05 
(corrected at cluster level). 
 
Statistical analyses  
Statistical analyses were performed using SPSS 20.0 for Windows (SPSS Inc., 
Chicago, IL, USA) and SPM8. Due to the non-normal distribution of data (as preliminary 
assessed by Shapiro-Wilk test), all between-group comparisons were tested by non-
parametric inferential statistical analyses (Kruskal-Wallis test and Mann-Whitney U test). 
For all analyses, the statistical threshold was set to p < 0.017 after Bonferroni correction 
for multiple comparisons (α = 0.05/3 = 0.017). 
Spearman correlation coefficient between WM-LL and GM fraction was assessed in all 
patients.   
Hierarchical multiple regression analyses between WM-LL as dependent variable 
and CSF Aβ, tau and Ptau levels as explanatory variables were conducted in the patient 
group. Each regression model was adjusted in order to control for the potential effect of 
age, gender, MMSE score, disease duration and GM fraction. Hierarchical multiple 
regression analyses were also investigated in the patient group by entering the GM 
fraction as dependent variable and CSF Aβ, tau and Ptau levels as explanatory 
variables. Again, each regression model was adjusted to control the potential effect of 
age, gender, MMSE and disease duration. CSF data from controls were not used for 
statistical analyses due to the smal sample size small (n=5). 
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RESULTS 
WM macrostructural damage 
Taken altogether, patients showed higher WM-LL than controls (U=16,000 p< 
0.001). In none of the groups, WM-LL correlated with the correspondent total GM 
fraction (r=-0.15, p=0.33). Using the Kruskal-Wallis test, we compared WM-LL across all 
groups, obtaining the following statistical values: 1) controls (mean rank 23.95); Aβ(+) 
patients (mean rank 54.25), Aβ(-) patients (mean rank 40.24) (χ2 20.54, df = 2, p < 
0.001). The pairwise comparisons showed higher WM-LL in Aβ(+) patients as compared 
to controls (p=0.003), and in Aβ(+)as compared to Aβ(-) patients (p=0.020). No 
significant differences were found between Aβ(-) patients and controls (p=0.078; Figure 
1). Regarding WM-LL, no significant differences were observed either in tau(+) 
compared with tau(-) patients (p=0.43), or in Ptau(+) compared with Ptau(-) patients 
(p=0.06). 
Multiple regression analysis showed CSF Aβ concentration to be a predictor of 
patients’ WM-LL (r=-0.30, p < 0.05, Figure 2). The percentage of variability of the 
regression model explained by CSF Aβ levels was 41% (p < 0.05). Patient’s age was a 
significant predictor (r=0.32, p < 0.05) of WM-LL, while, interestingly, disease duration 
and the level of global cognition (assessed by the MMSE score) were not (p > 0.05).  
 
Brain volumetrics 
As expected, total GM fraction was significantly lower in all patients compared to 
controls (34.35%±3.36% vs 41.40%±5.3%, p < 0.001). No significant differences in total 
GM fraction were observed between patients’ groups (34.76%±3.95% vs 
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34.03%±2.84%, p=0.398). When comparing patients against controls in a voxel-wise 
fashion to assess the regional GM atrophy, the two groups showed two distinct patterns. 
In Aβ(+) patients, GM atrophy involved, mainly, the medial temporal lobes. Conversely, 
in Aβ(-) patients, GM loss was prominent in the orbitofrontal cortices. Finally, when 
stratifying the Aβ(+) group for the severity of cognitive impairment (MMSE cut-off 
score=24), most impaired patients showed a trend towards significance of higher 
atrophy in their hippocampal and parahippocampal regions (p < 0.01 unc.; p < 0.05 
unc., respectively). 
 Multiple regression analysis showed CSF tau levels to be a predictor of patients’ 
GM atrophy (r=-0.27, p < 0.05). The percentage of variability of the regression model 
explained by CSF tau levels was 36% (p < 0.05). No other significant predictors were 
found.  
 
WM microstructural damage  
DWI analysis showed a significant increase of ADC values obtained by averaging 
all WM lesions in the brain, in patients versus controls (p < 0.0001, Figure 3a). 
Moreover, lesion ADC values in patients were significantly correlated with the 
correspondent WM-LL (r=0.41; p=0.001, Figure 3b). Conversely, no significant 
correlation was found between patients’ lesion ADC values and CSF Aβ and tau levels 
(p > 0.01). Concerning Aβ(+) and Aβ(-) patients, no significant difference about ADC 
values was found between-group. When considering Aβ(+) patients in isolation, their 
WM-LL was significantly correlated with the ADC values in the left peritrigonal area (p < 
0.0001).  
 
 
DISCUSSION 
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In this study, we recruited a group of patients with cognitive decline, classifying 
them as Aβ(+) and Aβ(-). Both groups were globally more atrophic than controls, but 
with a different pattern of regional GM atrophy. Consistent with previous findings31, AD 
patients showed a prominent atrophy in the medial temporal lobes, while non-AD 
patients presented with a more pronounced pattern of orbitofrontal GM atrophy. 
 With respect to macroscopic WM involvement, we first confirmed previous 
findings32 demonstrating that total WM-LL is significantly higher in patients with 
dementia than in healthy elderly individuals. Furthermore, we demonstrated that, even 
accounting for the aging effect, CSF Aβ levels are the best predictor for the 
accumulation of WMHs: the lower the CSF Aβ levels, the higher the total WMHs.  
Consistently, Aβ(+) patients showed significantly higher WM-LL when compared to 
either group, controls or Aβ(-) patients. These data support the hypothesis that the 
macroscopic WM damage is likely to reflect a pathogenic mechanism which is part of 
AD pathophysiology rather than expression of concomitant comorbidities. Whether this 
WM damage is strictly related to GM degeneration or is an independent process is still a 
matter of debate. According to our data, we suggest that WMHs are not necessarily 
associated to GM degeneration. We did not observe any significant difference in WM-LL 
when stratifying AD patients for disease duration and global cognition; so, we might 
argue that WMHs may occur at an early pathophysiological stage of AD. Notably, 
patients with Fazekas ≥2 were excluded in order to likely exclude any bias due to the 
presence of cerebrovascular disease. Moreover, patients included had a HIS <3. In any 
case, our findings confirm, along with previously published data,9,11,12,19,20 that WMHs 
should be regarded as a crucial feature of AD. 
Concerning the evidence here reported that CSF Aβ levels are the best predictor 
for WM-LL, age excluded, our results are in accordance with Lee et al., who found an 
association between the increase of WM-LL and the reduction of CSF Aβ levels in 
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autosomal dominant genetic forms of AD.21 This evidence suggests that WMHs and Aβ 
pathology may share some degree of correlation and, probably, some 
pathophysiological mechanism. 
 In this framework, our findings suggest that CSF Aβ reduction might be 
associated with the occurrence of WM metabolic damage due to Aβ deposition, possibly 
caused by impairment of pathways implicated in myelination and myelin repairing 
processes.33,34  
As argued by Prins and Scheltens, WMHs may represent only the extreme end of 
a continuous spectrum of WM injury, creating a need for imaging approaches able to 
detect subtler changes.8 Diffusion imaging is one of the most suitable techniques to 
assess WM integrity in vivo. The LADIS study showed that ADC values within the 
normal-appearing white matter (NAWM) of patients with cognitive impairment are 
associated to WM-LL.35 More recently, ADC changes in the NAWM were also 
demonstrated to precede the development of WMHs.36 In the current study, we used 
ADC maps to characterize the microstructural substrate of WM lesions in a Aβ(+) and 
Aβ(-) patients as compared to healthy elderly individuals. We found that the average 
ADC value across all WMHs was higher in both groups of patients compared to 
controls, thus indicating a different pathogenesis for lesions occurring in the brain of 
patients suffering from neurodegenerative dementia. Moreover, we found out that lesion 
ADC values in patients’ brains correlate with WM-LL. This result may not be surprising, 
but corroborates the speculation that there is a connection between the type and 
severity of WM microstructural damage and the macroscopic WM lesions themselves. 
Interestingly, our data revealed that WM-LL correlates with WM microstructural damage 
in the left peritrigonal WM in the Aβ(+) group compared to controls. These findings are 
consistent with the hypothesis that one of the early features of AD is WM microstructural 
damage, particularly in the left peritrigonal WM, a crucial area for AD pathology due to 
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its strong connections with the precuneus. As known, parietal areas represent the main 
node of integration between structural and functional brain networks.37 The precuneus 
is a notable area, not only due to its location deep in the postero-medial cortex of the 
parietal lobe, but also because of its possible role in fundamental cognitive 
functioning.38 Interestingly, it also shows exceptionally high levels of energy 
requirement.38  
Parietal dysfunction might contribute to the cognitive deficits that can be 
observed in the earliest stages of AD.39 In clinical practice, medial parietal areas 
hypometabolism is an accurate tool to differentiate cognitively healthy elderly individuals 
from early AD patients.40 Several studies in early AD patients have shown loss of WM 
volume or integrity, particular affecting medial parietal regions,39 resulting in metabolic 
dysfunction.39 Emerging evidence indicates that AD vulnerability is strongly associated 
with hyperconnectivity, augmented synaptic and metabolic activities, as well as 
functional plasticity. Speculations can be made about recent higher cortical functions 
carrying a risk for cognitive decline. We hypothesize that the development of newer 
cortical areas and the concomitant increase of synapse network might result in a higher 
structural instability, because of a major regional metabolic burden. This could result 
first in WM microstructural changes, and then in WM macrostructural damage. In light of 
this, the causal and temporal relationship between WM microstructural alterations and 
neurodegeneration needs to be further investigated, possibly in longitudinal studies.  
With regard to tau and Ptau proteins, no significant correlations were found, but 
considering the borderline p value (p=0.06), further studies would be needed to confirm 
these data. Conversely, in our cohort of patients, CSF tau protein levels resulted as a 
predictor of GM volume fraction. 
In conclusion, this study suggests that WM lesions and their micro-structural 
substrate, particularly in the left parietal areas, represent a crucial feature in AD, 
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independent of vascular risk factors and disease stage. Moreover, the correlation 
between CSF Aβ levels and total WMH volume seems to confirm a link between Aβ 
pathology and WM macro- and microstructural damage. Limitations of the study include 
the cross-sectional design, the small sample size, the absence of statistical analysis 
with healthy controls and the lack of more detailed neuropsychological description. 
Therefore, replication in a larger cohort of patients is required to confirm these data. 
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LIST OF THE ACRONYMS 
Aβ: β-amyloid1-42 
Aβ(+):  patients with pathological CSF Aβ levels 
Aβ(-):  patients with normal CSF Aβ levels 
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AD: Alzheimer's disease 
ADC: apparent diffusion coefficient 
CSF: cerebrospinal fluid 
DWI: diffusion weighted imaging 
FTD: frontotemporal dementia 
FWE: family wise error 
GM: grey matter 
HIS: Hachinski ischaemic score 
DLB: dementia with Lewy body 
LL: lesion load 
LP: lumbar puncture 
MCI: mild cognitive impairment 
MMSE: mini mental state examination 
MRI: magnetic resonance imaging 
MWF: myelin water fraction  
NAWM: normal appearing white matter 
PiB: 11C-Pittsburgh compound B 
Ptau: tau phosphorylated at position 181 
Tau: total tau 
TIV: total intracranial volume  
VaD: vascular dementia 
VBM: voxel based morphometry 
WM: white matter 
WMHs: white matter hyperintensities 
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Table 1: Clinical and demographic characteristics of healthy controls, AD patients with 
low CSF Aβ levels (Aβ(+)) and non-AD patients with high CSF Aβ levels (Aβ(-)).  
* Data available for five out of twenty subjects. Abbreviations: MMSE = mini mental state 
examination; WM-LL = white matter lesion load; CSF = cerebrospinal fluid; Aβ = β-amyloid; Ptau 
= 181-phospho-tau. 
 
 
 
 
Healthy controls  
(n = 20) 
mean±SD 
Aβ(+) – AD patients 
(n = 42) 
mean±SD 
Aβ(-) – non-AD patients 
(n = 23) 
mean±SD 
Age, y 
 
72.3 ± 9.8 74.22 ± 7.5 74.9 ± 4.8 
Female/male 
 
11/9 24/18 12/11 
Disease duration, m  
 
- 47 ± 42 43 ± 23 
MMSE, raw score 
 
29.10 ± 0.79 20.36 ± 6.04 20.08 ± 5.71 
WM-LL, mm3  
 
3302.95 ± 3964.11 8604.00 ± 6550.32 6876.86 ± 8025.32 
CSF Aβ, pg/ml 
 
1214.00 ± 186.92* 486.43 ± 111.06 843.74 ± 241.65 
CSF tau, pg/ml  
 
209.40 ± 93.73* 609.48 ± 371.12 430.48 ± 315.35 
CSF Ptau, pg/ml 
 
30.80 ± 15.48* 79.24 ± 30.79 60.43 ± 30.58 
 
 
